Multiple benefits with multilineage defense1

LEUKINE® (sargramostim) significantly reduced the risk of serious and fatal infection vs placebo in a phase 3, multicenter, randomized, double-blind, placebo-controlled study of patients following induction therapy for AML (N=99)1-3

Significantly decreased incidence of fatal infection1-3

Significantly decreased incidence of fatal infection chart

Significantly decreased incidence of serious infection1-3







Following allogeneic BMT, patients receiving LEUKINE® (sargramostim) experienced a reduced incidence of infection vs placebo in a multicenter, randomized, placebo-controlled, double-blind study (N=109)1

Significantly reduced incidence of infection1

Incidence of infection (P<0.05)


Incidence of Grade 3 and 4 mucositis (P<0.05)


Incidence of bacteremia (P<0.05)


LEUKINE safety and efficacy were evaluated in 3 single-center, randomized, placebo-controlled, double-blind studies of 128 patients undergoing autologous BMT. Efficacy data reflect a subpopulation of patients with NHL or ALL (N=104)1

Significantly reduced duration of infection, antibacterial therapy, and hospitalization1

LEUKINE® (sargramostim) reduced the duration of infection by 75%

vs placebo (1 day vs 4 days, respectively; P<0.05)

4-day reduction

of antibacterial therapy with LEUKINE vs placebo
(21 days vs 25 days, respectively; P<0.05)

6-day reduction

in length of hospitalization with LEUKINE vs placebo
(25 days vs 31 days, respectively; P<0.05)

LEUKINE® (sargramostim) provided a median survival benefit vs historical controls in a study of patients experiencing delayed or failed engraftment after allogeneic or autologous BMT1

Median survival benefit after
autologous BMT (N=85)1

474 days with Leukine vs. 161 days historical controls

Median survival benefit after
allogeneic BMT (N=158)1

97 days with Leukine vs. 35 days historical controls